MLV & Co Initiates Halozyme Therapeutics With Buy
December 24, 2014 at 07:11 AM EST
Analysts at MLV & Co initiated coverage on Halozyme Therapeutics, Inc. (NASDAQ: HALO) with a Buy rating. The target price for ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.